Explore more publications!
Sci-Tech Portal St. Lucia
Got News to Share?

Sci-Tech Portal St. Lucia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Portal St. Lucia.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on January 21, 2026

AMERICAN REBEL HOLIDNGS, INC. (NASDAQ: AREB) ANNOUNCES 1-FOR-20 REVERSE STOCK SPLIT WITH ROUND LOT SHAREHOLDER PROTECTION TO BE EFFECTIVE ON FEBRUARY 2, 2026, FOR ALL SHAREHOLDERS OF RECORD AS OF THE EFFECTIVE DATE
January 21, 2026

AMERICAN REBEL HOLIDNGS, INC. (NASDAQ: AREB) ANNOUNCES 1-FOR-20 REVERSE STOCK SPLIT WITH ROUND LOT SHAREHOLDER PROTECTION TO BE EFFECTIVE ON FEBRUARY 2, 2026, FOR ALL SHAREHOLDERS OF RECORD AS OF THE EFFECTIVE DATE

Indeterminate GlobeNewswire
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
January 21, 2026

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Indeterminate GlobeNewswire
Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™
January 21, 2026

Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™

Indeterminate GlobeNewswire
University of Virginia Announces First-in-Human Trial of Therapy for Sepsis-Induced Acute Respiratory Distress Syndrome
January 21, 2026

University of Virginia Announces First-in-Human Trial of Therapy for Sepsis-Induced Acute Respiratory Distress Syndrome

Indeterminate GlobeNewswire
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
January 21, 2026

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Indeterminate GlobeNewswire
Digital Realty Announces Tax Treatment of 2025 Dividends
January 21, 2026

Digital Realty Announces Tax Treatment of 2025 Dividends

Indeterminate GlobeNewswire
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
January 21, 2026

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
GRI Bio Announces Reverse Stock Split
January 21, 2026

GRI Bio Announces Reverse Stock Split

Indeterminate GlobeNewswire
CompoSecure, a Reporting Segment of GPGI, Inc, Announces CEO Transition
January 21, 2026

CompoSecure, a Reporting Segment of GPGI, Inc, Announces CEO Transition

Indeterminate GlobeNewswire
ZenaTech anuncia el nuevo dron ZenaDrone IQ Quad para apoyar el crecimiento en los mercados de topografía, construcción, planificación urbana y obras públicas
January 21, 2026

ZenaTech anuncia el nuevo dron ZenaDrone IQ Quad para apoyar el crecimiento en los mercados de topografía, construcción, planificación urbana y obras públicas

Indeterminate GlobeNewswire
UPDATE - BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
January 21, 2026

UPDATE - BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency

Indeterminate GlobeNewswire
Rezolve Ai Closes $250 Million Oversubscribed Financing, Enters 2026 With One of the Strongest Balance Sheets in AI Commerce
January 21, 2026

Rezolve Ai Closes $250 Million Oversubscribed Financing, Enters 2026 With One of the Strongest Balance Sheets in AI Commerce

Indeterminate GlobeNewswire
Gigamon Recognizes Top Global Partners at 2026 Sales Kickoff
January 21, 2026

Gigamon Recognizes Top Global Partners at 2026 Sales Kickoff

Indeterminate GlobeNewswire
Crunchafi Hosts Webinar to Help Firms Navigate Judgment Calls and “Fine Print” Under ASC 842
January 21, 2026

Crunchafi Hosts Webinar to Help Firms Navigate Judgment Calls and “Fine Print” Under ASC 842

Indeterminate GlobeNewswire
ESO Names Industry Veteran Sam Brown as President and COO
January 21, 2026

ESO Names Industry Veteran Sam Brown as President and COO

Indeterminate GlobeNewswire
ZIWO Joins AWS ISV Accelerate Program to Scale Cloud Contact Center Adoption
January 21, 2026

ZIWO Joins AWS ISV Accelerate Program to Scale Cloud Contact Center Adoption

Indeterminate GlobeNewswire
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
January 21, 2026

Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Indeterminate GlobeNewswire
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
January 21, 2026

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

Indeterminate GlobeNewswire
AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041
January 21, 2026

AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041

Indeterminate GlobeNewswire
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
January 21, 2026

OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions